BCKDHA

2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial is an enzyme that in humans is encoded by the BCKDHA gene.[5]

BCKDHA
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesBCKDHA, BCKDE1A, MSU, MSUD1, OVD1A, branched chain keto acid dehydrogenase E1, alpha polypeptide, branched chain keto acid dehydrogenase E1 subunit alpha
External IDsOMIM: 608348 MGI: 107701 HomoloGene: 569 GeneCards: BCKDHA
Gene location (Human)
Chr.Chromosome 19 (human)[1]
Band19q13.2Start41,397,808 bp[1]
End41,425,002 bp[1]
Orthologs
SpeciesHumanMouse
Entrez

593

12039

Ensembl

ENSG00000248098

ENSMUSG00000060376

UniProt

P12694

P50136

RefSeq (mRNA)

NM_001164783
NM_000709

NM_007533

RefSeq (protein)

NP_000700
NP_001158255

n/a

Location (UCSC)Chr 19: 41.4 – 41.43 MbChr 7: 25.63 – 25.66 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

BCKDHA is a coding gene that is part of the BCKD complex (branched-chain alpha-keto acid dehydrogenase).[6]

Discovery

BCKDHA was discovered by John Menkes in 1954. After he had seen a family with four children die after only a few months after birth, he found that their urine smelled sweet like maple syrup. While he was not the one to discover the specific gene, he did discover the maple syrup urine disease [7](MSUD). The BCKD complex is made up of three different catalytic pieces. It was in 1960 when Dancis discovered the gene itself, but this was from Menkes discovering of the disease leading to further investigation of its origin. He found that looking at the branched-chain amino acids and their corresponding alpha-keto acids, in turn aided in the realization that they were pathogenetic compounds. Dancis was the one to specifically track down the enzymatic defect in (MSUD) by finding what gene in the pool of human chromosomes was defecting the urine. He found the gene on the level of the decarboxylation of the branched-chain amino acids.[8]

Gene location

The cytogenetic location of BCKDHA is on the human chromosome 19, specifically on the cytogenetic band at 19q13.2. This the long arm (q) of the chromosome 19 at 13.2. Looking at the molecular location, the base pairs 41,397,789 to 41,425,005 are on chromosome 19. The cellular localization of this gene is within the mitochondrion matrix.[9]

Function

The second major step in the catabolism of the branched-chain amino acids, isoleucine, leucine, and valine, is catalyzed by the branched-chain alpha-keto acid dehydrogenase complex (BCKD; EC 1.2.4.4), an inner-mitochondrial enzyme complex that consists of 3 catalytic components: a heterotetrameric (alpha2, beta2) branched-chain alpha-keto acid decarboxylase (E1), a homo-24-meric dihydrolipoyl transacylase (E2; MIM 248610), and a homodimeric dihydrolipoamide dehydrogenase (E3; MIM 238331). The reaction is irreversible and constitutes the first committed step in BCAA oxidation. The complex also contains 2 regulatory enzymes, a kinase and a phosphorylase. The BCKDHA gene encodes the alpha subunit of E1, and the BCKDHB gene (MIM 248611) encodes the beta subunit of E1.[supplied by OMIM][5]

The normal function of the BCKDHA gene is to provide instructions for making the alpha subunit of the branched-chain alpha-keto dehydrogenase (BCKD) enzyme complex. The alpha subunit is one part of the BCKD enzyme complex. Two beta subunits are produced from the BCKDHB gene [10] and connect to two alpha subunits to form the E1 (decarboxylase) component. The BCKD enzyme complex catalyzes one step in breaking down amino acids. Those amino acids being leucine, isoleucine, and valine. The BCKD enzyme complex can be found in the mitochondria, an organelle known as the powerhouse of the cell. All three amino acids can be found in protein-rich foods and when broken down, they can be used for energy. Mutations in the BCKDHA gene can lead to maple syrup urine disease.[11]

Clinical significance

Mutations in the BCKDHA gene occur due to single point mutations in the “alpha subunit of the BCKD enzyme complex”.[7] Earlier cases of this disease show the mutation more frequently occurred by replacing the amino acid tyrosine. This amino acid was replaced with asparagine. The complication with mutations in the BCKDHA gene is that it disrupts the normal function of the BCKD enzyme complex; preventing the gene essentially from going about its normal functions. So, the BCKDHA gene would not be able to break down leucine, isoleucine, and valine. When these byproducts start to accumulate it produces a toxic environment for cells and tissues, specifically in the nervous system. This can lead to seizures, developmental delay, but most importantly maple syrup urine disease.

The BCKDHA has been pinpointed in people with maple syrup urine disease, due to over 80 mutations occurring in that gene. Severe symptoms arise from these mutations and cause the disease which shows soon after birth. Due to the sweet odor from the urine, the disease was termed maple syrup urine disease. The disease causes loss of appetite, nausea, lethargy, and delayed development.

BCKDHA mutation: maple syrup urine disease

Maple syrup urine disease is an “autosomal recessive inborn error of metabolism. Meaning, as stated earlier, that there is a defect (i.e. error) in the single gene that codes for an enzyme. These enzymes promote conversions for various substrates into products. In terms of maple syrup urine disease, the enzyme defect occurs in the metabolic pathway of the “branched-chain amino acids” leucine, isoleucine, and valine.[10] The buildup of these amino acids lead to “encephalopathy and progressive neurodegeneration”;[10] along with other complications.

There are five forms of maple syrup urine disease: intermediate, intermittent, thiamine-responsive and E3 deficient. The form of disease is dependent upon clinical prognosis, dietary protein tolerance, and thiamine response and level of enzyme activity. Intermediate maple syrup urine disease is a milder form of maple syrup urine disease because it persistently raises branched-chain amino acids and some keto-acid chains. Individuals with this disease have a partial BCKDHA enzyme deficiency.[7] Meaning that it shows up sporadically or reacts to dietary thiamine therapy.

gollark: Why not just make the PCB store all possible passwords in advance?
gollark: GTech™ simply retroactively arranges the universe such that only the authorized user ever logs in.
gollark: Ah, how secure, users will have to set their passwords every time the server restarts.
gollark: BRB, making a hardware implementation of CPython `hash` to bruteforce your passwords.
gollark: How ethical.

References
  1. GRCh38: Ensembl release 89: ENSG00000248098 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000060376 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. "Entrez Gene: BCKDHA branched chain keto acid dehydrogenase E1, alpha polypeptide".
  6. "MTSU -- Ezproxy Login". eds.a.ebscohost.com.ezproxy.mtsu.edu. Retrieved 2018-11-18.
  7. Reference, Genetics Home. "BCKDHA gene". Genetics Home Reference. Retrieved 2018-11-14.
  8. Reference, Genetics Home. "BCKDHA gene". Genetics Home Reference. Retrieved 2018-11-15.
  9. "BCKDHA branched chain keto acid dehydrogenase E1, alpha polypeptide". NCBI. Retrieved 12 April 2019.
  10. Database, GeneCards Human Gene. "BCKDHA Gene - GeneCards | ODBA Protein | ODBA Antibody". www.genecards.org. Retrieved 2018-11-14.
  11. Database, GeneCards Human Gene. "BCKDHA Gene - GeneCards | ODBA Protein | ODBA Antibody". www.genecards.org. Retrieved 2018-11-15.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.